Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Korean Post-marketing Surveillance for Xeljanz(Registered) in Rheumatoid Arthritis and Psoriatic Arthritis Patients

NCT02984020 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02984020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02984020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Korean Post-marketing Surveillance for Xeljanz(Registered) in Rheumatoid Arthritis and Psoriatic Arthritis Patients
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
May 13, 2016
Completion date
June 9, 2022
Enrollment
1,041 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis, rheumatoid arthritis